| About |
| About |
| About |
Fluid is a Stanford University spinout company that enables users to track and diagnose influenza and other infectious disease using their mobile phone. Fluid's technology combines user-collected information with large healthcare datasets to create personalized risk assessments.
Fluid is a Stanford University spinout company that enables users to track and diagnose influenza and other infectious disease using their mobile phone. Fluid's technology combines user-collected information with large healthcare datasets to create personalized risk assessments.
Fluid is a Stanford University spinout company that enables users to track and diagnose influenza and other infectious disease using their mobile phone. Fluid's technology combines user-collected information with large healthcare datasets to create personalized risk assessments.
The current explosion of public health data represents a turning point in health information. However, in its current form, much of this data is inaccessible to everyday people. Fluid's platform combines personalized, user-collected data with real-time public information on infectious disease to improve awareness, enhance behavior, and enable more people to benefit from clinical treatment.
The current explosion of public health data represents a turning point in health information. However, in its current form, much of this data is inaccessible to everyday people. Fluid's platform combines personalized, user-collected data with real-time public information on infectious disease to improve awareness, enhance behavior, and enable more people to benefit from clinical treatment.
The current explosion of public health data represents a turning point in health information. However, in its current form, much of this data is inaccessible to everyday people. Fluid's platform combines personalized, user-collected data with real-time public information on infectious disease to improve awareness, enhance behavior, and enable more people to benefit from clinical treatment.
| Who we are |
| Who we are |
| Who we are |
Adam Siegel
Adam Siegel
Adam Siegel
Adam is an entrepreneur focused on technology and business development in mobile health. Previously at Google X and Harvard, he is inventor on nine patents and author of ten publications on point-of-care diagnostics. Adam co-developed the core technologies of Claros Diagnostics (acquired by Opko in 2011) and nonprofit Diagnostics-For-All, which raised $10 M from the Bill & Melinda Gates Foundation.
Adam is an entrepreneur focused on technology and business development in mobile health. Previously at Google X and Harvard, he is inventor on nine patents and author of ten publications on point-of-care diagnostics. Adam co-developed the core technologies of Claros Diagnostics (acquired by Opko in 2011) and nonprofit Diagnostics-For-All, which raised $10 M from the Bill & Melinda Gates Foundation.
Adam is an entrepreneur focused on technology and business development in mobile health. Previously at Google X and Harvard, he is inventor on nine patents and author of ten publications on point-of-care diagnostics. Adam co-developed the core technologies of Claros Diagnostics (acquired by Opko in 2011) and nonprofit Diagnostics-For-All, which raised $10 M from the Bill & Melinda Gates Foundation.
Micah Siegel
Micah Siegel
Micah Siegel
Micah is a Stanford professor whose research spans mobile healthcare, big data, consumer electronics, and enterprise software. He is the founding investor in new companies which have raised more than $70 M in follow-on financing. Most recently, Micah has been a seed-stage investor and adviser to BioImagene (acquired in 2010 by Roche for $100 M in cash), Stack Exchange, Hadapt, and Judicata.
Micah is a Stanford professor whose research spans mobile healthcare, big data, consumer electronics, and enterprise software. He is the founding investor in new companies which have raised more than $70 M in follow-on financing. Most recently, Micah has been a seed-stage investor and adviser to BioImagene (acquired in 2010 by Roche for $100 M in cash), Stack Exchange, Hadapt, and Judicata.
Micah is a Stanford professor whose research spans mobile healthcare, big data, consumer electronics, and enterprise software. He is the founding investor in new companies which have raised more than $70 M in follow-on financing. Most recently, Micah has been a seed-stage investor and adviser to BioImagene (acquired in 2010 by Roche for $100 M in cash), Stack Exchange, Hadapt, and Judicata.
| Contact |
| Contact |
| Contact |
Fluid, Inc.
Fluid, Inc.
Fluid, Inc.
615 Grant Avenue, Third Floor
615 Grant Avenue, Third Floor
615 Grant Avenue, Third Floor
San Francisco, CA 94133
San Francisco, CA 94133
San Francisco, CA 94133
© 2015 Fluid, Inc.
© 2015 Fluid, Inc.